HLB PHARMACEUTICAL Announces 32.81% Rights Offering, Raising Concerns Over Share Dilution and Funding for Facilities, Operations, and Debt Repayment
HLB PHARMACEUTICAL has decided on a rights offering followed by a public offering of unsubscribed shares, issuing 10,762,332 new shares to raise a total of 120 billion KRW for facility investment of 55 billion KRW, operating funds of 50 billion KRW, and debt repayment of 15 billion KRW.
The expected offering price is 11,150 KRW, representing a discount of approximately 15% from the current price of 13,140 KRW, and the dilution ratio is 32.81%, significantly diluting existing shareholders.
The company adjusted the schedule: the record date is changed to August 5, 2026, subscription period for existing shareholders to September 10-11, payment date to September 18, and listing date to October 7.
There is no plan for share buyback or cancellation, and the new share subscription warrants will be listed for trading.
[AI Summary]HLB PHARMACEUTICAL's rights offering imposes a heavy burden on existing shareholders due to a high dilution ratio of 32.81% and a 15% discount to market price. The use of proceeds focuses on financial stability through facility investment, working capital, and debt repayment rather than immediate growth drivers. While underwriters such as Korea Investment & Securities and Hana Securities reduce placement risk, the large volume of new shares may exert downward pressure on the stock price, warranting investor caution.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)